KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Payables (2016 - 2025)

Historic Payables for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $11.1 million.

  • CRISPR Therapeutics AG's Payables fell 2427.77% to $11.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.1 million, marking a year-over-year decrease of 2427.77%. This contributed to the annual value of $11.1 million for FY2025, which is 2427.77% down from last year.
  • CRISPR Therapeutics AG's Payables amounted to $11.1 million in Q4 2025, which was down 2427.77% from $11.8 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Payables peaked at $45.2 million during Q1 2023, and registered a low of $9.5 million during Q2 2024.
  • Moreover, its 5-year median value for Payables was $15.2 million (2021), whereas its average is $20.0 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Payables surged by 21586.51% in 2022, and later tumbled by 6573.87% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Payables (Quarter) stood at $14.8 million in 2021, then skyrocketed by 85.12% to $27.4 million in 2022, then surged by 39.08% to $38.1 million in 2023, then crashed by 61.44% to $14.7 million in 2024, then dropped by 24.28% to $11.1 million in 2025.
  • Its Payables stands at $11.1 million for Q4 2025, versus $11.8 million for Q3 2025 and $9.8 million for Q2 2025.